Unicycive Therapeutics' OLC shows promise in treating hyperphosphatemia by reducing pill burden and adverse events, potentially gaining FDA approval by June 2025.
The FDA has accepted Unicycive Therapeutics' New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) with a PDUFA target action date of June 28, 2025.
Unicycive Therapeutics' oxylanthanum carbonate (OLC) is under FDA review for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
The FDA has accepted Unicycive Therapeutics' New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.